Views & Analysis
What should industry consider next time

VPAS 2024: What should industry consider next time?

The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded medicines spend; the 2019 Voluntary Scheme for Branded Medicines Pricing

News
TevaCanada2

Teva vows to fight price-fixing lawsuit

Teva has said it will defend itself against a lawsuit raised by 44 US states that alleges the company was the ringleader in an illegal price-fixing scheme involving 19 other generic compani

News

Press Releases

Views & Analysis

Newsletters and Deep Dive
digital magazine

Webinars

Podcasts

Video

White Papers

Spotlight on
Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Debates & Insight
PMA 2015 2016
Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Debates & Insight

Partner Content